Pharmacodynamics, safety, tolerability, and pharmacokinetics of the 0.8- mg dose of Cerivastatin in patients with primary hypercholesterolemia

American Journal of Cardiology

Volumn 83, Issue 10, 1999, Pages 1433-1436

  Stein, Evan ^a   Isaacsohn, Jonathan ^a   Stoltz, Randall ^b   Mazzu, Arthur ^c   Liu, Ming Chung ^c   Lane, Cindy ^c   Heller, Allen H ^c  

^a Metabolic and Atherosclerosis Research Center   (United States)

^b GFI Pharmaceutical Services Inc   (United States)

^c BAYER CORPORATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CERIVASTATIN; CHOLESTEROL; CREATINE KINASE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; TRIACYLGLYCEROL;

ADULT; AGED; AREA UNDER THE CURVE; ARTHRALGIA; ARTHRITIS; ARTICLE; BACKACHE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIET THERAPY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HEADACHE; HEEL; HUMAN; HYPERCHOLESTEROLEMIA; LIPID BLOOD LEVEL; MALE; PHARMACODYNAMICS; PHARMACOKINETICS; PHARYNGITIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; SINGLE BLIND PROCEDURE;

CHOLESTEROL, LDL; DOUBLE-BLIND METHOD; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; MALE; PYRIDINES;

EID: 0033562524     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9149(99)00120-4     Document Type: Article

References (12)

1. Insull W., Stein E., Whalen E., Ripa S. Cerivastatin a new potent HMG-CoA reductase inhibitor: efficacy and tolerability in primary hypercholesterolemia . J Am Coll Cardiol. 29:1997;46A.
2. Mazzu A., Lettieri J., Heller A.H. Pharmacokinetics of cerivastatin administration with and without food in the morning and evening. Atherosclerosis. 139:(suppl):1997;S29.
3. Sachse R., Brendel E., Muck W., Rohde G., Ochmann K., Horstmann R. No drug-drug interaction between cerivastatin and nifedipine. Arch Pharmacol. 357:1998;R174.
4. Muck W., Ochmann K., Rohde G., Unger S., Kuhlmann J. No drug-drug interactions between cerivastatin and omeprazole. Arch Pharmacol. 357:1998;R175.
5. Frey R., Ritter W., Unger S., Ochmann K., Wingenzer W. Phase I study to investigate the effects of cimetidine on the pharmacokinetics of cerivastatin - a new HMG-CoA reductase inhibitor. Atherosclerosis. 130:1997;S27.
6. Muck W., Ritter W., Dietrich H., Frey R., Kuhlmann J. Influence of the antiacid Maalox® and the H2-antagonist cimetidine on the pharmacokinetics of cerivastatin. Int J Clin Pharmacol Ther. 35:1997;261-264.
7. Lettieri J.T., Krol G.J., Mazzu A., Fiebach M.Z., Heller A.H. Lack of pharmacokinetic interaction between cerivastatin, a new HMG-CoA reductase inhibitor, and digoxin. Atherosclerosis. 130:1997;S29.
8. Schall R., Muller F.O., Hundt H.K., Ritter W., Duursema L., Groenewoud G. No pharmacokinetic or pharmacodynamic interaction between rivastatin and warfarin. J Clin Pharmacol. 35:1995;306-313.
9. Myers G.L., Cooper G.R., Winn C.L., Smith S.J. The Centers for Disease Control-National Heart, Lung and Blood Institute Lipid Standardization Program an approach to accurate and precise lipid measurements . Clin Lab Med. 9:1989;105-135.
10. Krol G.J., Beck G.W., Ritter W., Lettieri J.T. LC separation and induced fluorometric detection of rivastatin in blood plasma. J Pharm Biomed Anal. 11:1993;1269-1275.
11. Krol G.J., Beck G.W., Ritter W., Lettieri J.T., Ness G.C., Lopez D. Determination of rivastatin levels in plasma samples by HPLC and enzyme inhibition assays. Reid R., Wilson I.D. Biofluid and Tissue Analysis for Drugs, Including Hypolipidaemics. 23 vol. 1994;147-156 Royal Society of Chemistry, Cambridge.
12. Management of dyslipidemia in adults with diabetes. American Diabetes Association. Diabetes Care 1998;21:179-182.